- South Korea
- /
- Biotech
- /
- KOSE:A011000
GeneOne Life Science Third Quarter 2024 Earnings: ₩255 loss per share (vs ₩148 loss in 3Q 2023)
GeneOne Life Science (KRX:011000) Third Quarter 2024 Results
Key Financial Results
- Revenue: ₩8.89b (down 24% from 3Q 2023).
- Net loss: ₩10.6b (loss narrowed by 8.3% from 3Q 2023).
- ₩255 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
GeneOne Life Science shares are up 5.0% from a week ago.
Risk Analysis
Before you take the next step you should know about the 2 warning signs for GeneOne Life Science that we have uncovered.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KOSE:A011000
GeneOne Life Science
A biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals.
Mediocre balance sheet and slightly overvalued.
